Pamufetinib mesylate - 10mM in DMSO, high purity , CAS No.1688673-09-7(DMSO)

  • 10mM in DMSO
Item Number
P655845
Grouped product items
SKUSizeAvailabilityPrice Qty
P655845-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$270.90

Basic Description

Specifications & Purity10mM in DMSO
Biochemical and Physiological MechanismsPamufetinib (TAS-115) mesylate is a potent VEGFR and hepatocyte growth factor receptor ( c-Met/HGFR )-targeted kinase inhibitor, with IC 50 s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
Storage TempDesiccated,Store at -80°C
Shipped InIce chest + Ice pads
Product Description

Pamufetinib (TAS-115) mesylate is a potent VEGFR and hepatocyte growth factor receptor ( c-Met/HGFR )-targeted kinase inhibitor, with IC 50 s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

In Vitro

Pamufetinib mesylate powerfully suppresses the VEGF-dependent proliferation of HUVECs (IC 50 =0.019 μM) as a VEGFR-targeted inhibitor and powerfully suppresses the proliferation of MET-amplified cancer cells (GI 50 =0.032-0.362 μM) as a MET-targeted inhibitor. Pamufetinib mesylate has much less toxicity in various normal cell lines when compared with other VEGFR-targeted kinase inhibitors. Crizotinib and Pamufetinib mesylate inhibit Met phosphorylation and reverse erlotinib resistance and VEGF production triggered by HGF in PC-9 and HCC827 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pamufetinib mesylate completely suppresses the progression of MET-inactivated tumor by blocking angiogenesis without toxicity when given every day for 6 weeks, even at a serum-saturating dose of Pamufetinib mesylate. Pamufetinib mesylate induces marked tumor shrinkage and prolonges survival in MET-amplified human cancer–bearing mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay

Tumor cells (8000 cells/800 mL) with or without TAS-115 (1.0 μM) or erlotinib (0.3 μM) in the lower Transwell collagen–coated chambers are cocultured with MRC-5 (1000 cells/300 μL) cells in the upper chamber for 72 hours. The upper chamber is then removed. Cell viability is measured using the MTT assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:IC50: 30 nM (rVEGFR2), 32 nM (rMET)

Names and Identifiers

Canonical SMILES CNC(=O)C1=CC2=C(C=CN=C2C=C1OC)OC3=C(C=C(C=C3)NC(=S)NC(=O)CC4=CC=CC=C4)F.CS(=O)(=O)O
Molecular Weight 614.66

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

Solution Calculators